huahaipharm(SH:600521)2020-04-29 16:00Financial Performance - Operating revenue for the period was CNY 1,570,555,260.04, representing a year-on-year increase of 30.98%[4] - Net profit attributable to shareholders was CNY 220,665,904.93, an increase of 62.74% compared to the same period last year[4] - Basic earnings per share were CNY 0.17, reflecting a growth of 54.55% compared to the previous year[4] - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which was CNY 197,433,041.53, up 94.37% year-on-year[4] - The company's operating revenue for the current period reached ¥1,570,555,260.04, an increase of ¥371,475,043.77 or 31% compared to the same period last year, primarily driven by significant sales growth in domestic formulations and active pharmaceutical ingredients[10] - The net profit attributable to the parent company was ¥220,665,904.93, reflecting an increase of ¥85,069,337.73 or 63% year-over-year, largely due to the substantial rise in sales of domestic formulations and active pharmaceutical ingredients[12] - The company reported a total profit of approximately $291.35 million for Q1 2020, compared to $167.82 million in Q1 2019, marking a 73.5% increase[22] - The company’s total comprehensive income for Q1 2020 was approximately $234.98 million, compared to $134.65 million in Q1 2019, reflecting a 74.4% increase[22] Cash Flow - Net cash flow from operating activities reached CNY 355,186,655.53, up 52.83% year-on-year[4] - The net cash flow from operating activities was CNY 355.19 million in Q1 2020, compared to CNY 232.41 million in Q1 2019, representing an increase of approximately 52.7%[27] - Cash inflow from operating activities totaled CNY 1.51 billion in Q1 2020, up from CNY 1.42 billion in Q1 2019, indicating a growth of about 6.5%[27] - The total cash inflow from operating activities was CNY 1.04 billion in Q1 2020, slightly down from CNY 1.09 billion in Q1 2019, reflecting a decrease of approximately 4.5%[29] - The cash flow from investment activities showed a net outflow of CNY 232.83 million in Q1 2020, compared to a net outflow of CNY 188.38 million in Q1 2019, indicating a worsening of about 23.6%[27] - The net cash flow from financing activities was negative CNY 389.03 million in Q1 2020, a decrease from a positive CNY 540.06 million in Q1 2019[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,565,255,086.08, a decrease of 1.53% compared to the end of the previous year[4] - Total liabilities decreased to ¥4,550,725,475.77 from ¥4,950,605,818.84, a reduction of approximately 8.06%[18] - Current assets totaled ¥4,270,502,507.77, down from ¥4,815,118,389.41, representing a decline of about 11.35%[19] - The company's inventory decreased to ¥2,047,925,647.04, down by ¥169,100,451.88 or 7.6% compared to the previous year[16] - Long-term borrowings increased to ¥1,423,946,550.00, up from ¥1,179,193,181.50, indicating a strategic move to leverage debt for growth[17] - Total equity rose to ¥6,686,881,026.44 from ¥6,478,286,034.66, reflecting an increase of approximately 3.22%[20] Shareholder Information - The number of shareholders at the end of the reporting period was 36,663[7] - The top shareholder, Chen Baohua, held 25.14% of the shares, amounting to 332,452,668 shares[7] Expenses - Sales expenses increased to ¥310,552,877.84, up by ¥123,887,282.30 or 66%, mainly due to intensified sales efforts for domestic formulations and market research to support new product launches[10] - Research and development expenses for Q1 2020 were approximately $115.97 million, up from $98.37 million in Q1 2019, indicating a 17.9% increase[21] Other Financial Metrics - The weighted average return on equity increased by 0.58 percentage points to 3.86%[4] - Financial expenses decreased significantly to ¥5,349,040.99, down by ¥52,398,704.01 or 91%, mainly due to reduced bank borrowings and corresponding interest expenses[12] - The company experienced a decrease in investment income, reporting a loss of approximately $7.19 million in Q1 2020 compared to a loss of $4.26 million in Q1 2019[21] - Other comprehensive income after tax for Q1 2020 was approximately $2.67 million, compared to a loss of $5.56 million in Q1 2019[22]